0001019056-20-000451.txt : 20200804 0001019056-20-000451.hdr.sgml : 20200804 20200731165010 ACCESSION NUMBER: 0001019056-20-000451 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200727 FILED AS OF DATE: 20200729 DATE AS OF CHANGE: 20200731 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gross Jane A CENTRAL INDEX KEY: 0001684258 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37746 FILM NUMBER: 201066617 MAIL ADDRESS: STREET 1: 2401 4TH AVENUE, SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aptevo Therapeutics Inc. CENTRAL INDEX KEY: 0001671584 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811567056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 206-838-0500 MAIL ADDRESS: STREET 1: 2401 4TH AVE. STREET 2: SUITE 1050 CITY: SEATTLE STATE: WA ZIP: 98121 4 1 gross.xml X0306 4 2020-07-27 0 0001671584 Aptevo Therapeutics Inc. APVO 0001684258 Gross Jane A C/O APTEVO THERAPEUTICS INC. 2401 4TH AVENUE, SUITE 1050 SEATTLE WA 98121 0 1 0 0 SVP & Chief Scientific Officer Stock Option (right to buy) 34.58 2020-07-27 4 D 0 2072 D 2021-03-10 Common Stock 2072 0 D Stock Option (right to buy) 35.70 2020-07-27 4 D 0 2779 D 2022-03-09 Common Stock 2779 0 D Stock Option (right to buy) 41.58 2020-07-27 4 D 0 3908 D 2026-02-28 Common Stock 3908 0 D Stock Option (right to buy) 27.44 2020-07-27 4 D 0 2407 D 2027-02-24 Common Stock 2407 0 D Stock Option (right to buy) 30.10 2020-07-27 4 D 0 2407 D 2027-06-01 Common Stock 2407 0 D Stock Option (right to buy) 43.82 2020-07-27 4 D 0 4814 D 2028-03-09 Common Stock 4814 0 D Stock Option (right to buy) 21.28 2020-07-27 4 D 0 4814 D 2029-02-28 Common Stock 4814 0 D Stock Option (right to buy) 8.56 2020-07-27 4 A 0 7784 A 2030-07-26 Common Stock 7784 7784 D Stock Option (right to buy) 8.56 2020-07-27 4 A 0 2140 A 2030-07-26 Common Stock 2140 2140 D Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. This stock option award vested on March 10, 2017. This award was originally part of a grant from Emergent BioSolutions Inc. ("Emergent") dated March 11, 2014, of which two-thirds were vested at the time of conversion to the issuer's equity pool. In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. This stock option award vested on March 10, 2018. This award was originally part of a grant from Emergent dated March 11, 2015, of which two-thirds were vested at the time of conversion to the issuer's equity pool. This stock option award vested over three years, and the final one-third vested on March 1, 2019. This stock option award vested over three years, and the final one-third vested on February 24, 2020. This stock option award vested over three years, and the final one-third vested on June 1, 2020. This stock option award provides for vesting in three approximately equal annual installments beginning on March 9, 2019. Prior to July 27, 2020, all but 1,605 shares of the issuer's common stock underlying this stock option had vested. This stock option award provides for vesting in three approximately equal annual installments beginning on February 28, 2020. Prior to July 27, 2020, all but 3,210 shares of the issuer's common stock underlying this stock option had vested. These options vest in full on the one year anniversary of the date of grant. These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. /s/ Carl A. Valenstein, attorney-in-fact 2020-07-29